Marshall Wace LLP Has $33.60 Million Stock Holdings in LivaNova PLC (NASDAQ:LIVN)

Marshall Wace LLP boosted its holdings in LivaNova PLC (NASDAQ:LIVN - Free Report) by 49.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 725,593 shares of the company's stock after purchasing an additional 239,227 shares during the quarter. Marshall Wace LLP owned 1.34% of LivaNova worth $33,602,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. increased its holdings in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock valued at $70,000 after buying an additional 219 shares during the period. Sterling Capital Management LLC grew its holdings in shares of LivaNova by 800.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock valued at $75,000 after purchasing an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division grew its holdings in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock valued at $191,000 after purchasing an additional 720 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova during the 4th quarter valued at approximately $204,000. Finally, Optimize Financial Inc bought a new stake in shares of LivaNova during the 4th quarter valued at approximately $208,000. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Stock Up 1.7 %

LIVN traded up $0.62 during midday trading on Thursday, hitting $36.95. The company had a trading volume of 107,186 shares, compared to its average volume of 669,929. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 87.98 and a beta of 0.90. The stock's 50 day moving average price is $39.35 and its 200 day moving average price is $46.39. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.47.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. StockNews.com raised shares of LivaNova from a "buy" rating to a "strong-buy" rating in a report on Tuesday, March 25th. Barclays reduced their target price on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating on the stock in a report on Friday, March 7th. Finally, Mizuho reduced their target price on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, LivaNova has an average rating of "Buy" and a consensus price target of $61.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.